Last updated on February 2018

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit/Hyperactivity Disorder


Brief description of study

To evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD). Subjects will be enrolled into this study from antecedent study SPD489-211 (NCT02402166) or SPD489-347.

Clinical Study Identifier: NCT02466386

Contact Investigators or Research Sites near you

Start Over

Shire Contact

Jersey Shore University Medical Center (JSUMC)
Neptune, NJ United States
  Connect »